Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia

Background Several studies of pediatric acute myeloid leukemia have described the various type-I or type-II aberrations and their relationship with clinical outcome. However, there has been no recent comprehensive overview of these genetic aberrations in one large pediatric acute myeloid leukemia cohort. Design and Methods We studied the different genetic aberrations, their associations and their impact on prognosis in a large pediatric acute myeloid leukemia series (n=506). Karyotypes were studied, and hotspot regions of NPM1, CEPBA, MLL, WT1, FLT3, N-RAS, K-RAS, PTPN11 and KIT were screened for mutations of available samples. The mutational status of all type-I and type-II aberrations was available in 330 and 263 cases, respectively. Survival analysis was performed in a subset (n=385) treated on consecutive acute myeloid leukemia Berlin-Frankfurt-Munster Study Group and Dutch Childhood Oncology Group treatment protocols. Results Genetic aberrations were associated with specific clinical characteristics, e.g. significantly higher diagnostic white blood cell counts in MLL-rearranged, WT1-mutated and FLT3-ITD-positive acute myeloid leukemia. Furthermore, there was a significant difference in the distribution of these aberrations between children below and above the age of two years. Non-random associations, e.g. KIT mutations with core-binding factor acute myeloid leukemia, and FLT3-ITD with t(15;17)(q22;q21), NPM1- and WT1-mutated acute myeloid leukemia, respectively, were observed. Multivariate analysis revealed a ‘favorable karyotype’, i.e. t(15;17)(q22;q21), t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22). NPM1 and CEBPA double mutations were independent factors for favorable event-free survival. WT1 mutations combined with FLT3-ITD showed the worst outcome for 5-year overall survival (22±14%) and 5-year event-free survival (20±13%), although it was not an independent factor in multivariate analysis. Conclusions Integrative analysis of type-I and type-II aberrations provides an insight into the frequencies, non-random associations and prognostic impact of the various aberrations, reflecting the heterogeneity of pediatric acute myeloid leukemia. These aberrations are likely to guide the stratification of pediatric acute myeloid leukemia and may direct the development of targeted therapies.

[1]  O. Aleinikova,et al.  AML1/RUNX1 gene point mutations in childhood myeloid malignancies , 2011, Pediatric blood & cancer.

[2]  S. Raimondi,et al.  Leukemic mutations in the methylation‐associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group , 2011, Pediatric blood & cancer.

[3]  J. Licht,et al.  DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.

[4]  B. Smith,et al.  FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. , 2011, Blood.

[5]  R. Andrews,et al.  Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice , 2011, Nature Genetics.

[6]  Torsten Haferlach,et al.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Hills,et al.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Schmitz,et al.  Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial , 2010 .

[9]  D. Reinhardt,et al.  Excellent Outcome In Infants below One Year of Age with AML – Results of Studies AML-BFM -98 and -2004 , 2010 .

[10]  R. Pieters,et al.  No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Taki,et al.  High frequencies of simultaneous FLT3-ITD, WT1 and KIT mutations in hematological malignancies with NUP98-fusion genes , 2010, Leukemia.

[12]  S. Raimondi,et al.  Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2010, Blood.

[13]  Manuela Zucknick,et al.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Pieters,et al.  Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. , 2010, European journal of cancer.

[15]  M. McDevitt,et al.  A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias , 2010, Leukemia.

[16]  E. van den Berg,et al.  Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  O. Haas,et al.  Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  I. Bernstein,et al.  Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study , 2010, Leukemia.

[19]  I. Bernstein,et al.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. , 2010, Blood.

[20]  S. Raimondi,et al.  Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. , 2009, Blood.

[21]  J. Downing,et al.  Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia , 2009, Proceedings of the National Academy of Sciences.

[22]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[23]  E. Thiel,et al.  A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. , 2009, Blood.

[24]  R. Pieters,et al.  Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. , 2009, Blood.

[25]  S. Raimondi,et al.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2009, Blood.

[26]  Rakesh Nagarajan,et al.  Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. , 2008, Blood.

[27]  R. Pieters,et al.  Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. , 2008, Blood.

[28]  C. S. Swindle,et al.  FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia. , 2008, Blood.

[29]  R. Schlenk,et al.  Significance of age in acute myeloid leukemia patients younger than 30 years , 2008, Cancer.

[30]  S. Fröhling,et al.  High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. , 2007, Blood.

[31]  Andrew P. Stubbs,et al.  The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. , 2007, Blood.

[32]  C. Zwaan,et al.  Pediatric acute myeloid leukemia: towards high-quality cure of all patients , 2007, Haematologica.

[33]  J. Downing,et al.  Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias , 2007, Leukemia.

[34]  M. Minden,et al.  A tumor suppressor and oncogene: the WT1 story , 2007, Leukemia.

[35]  K. Takamiya,et al.  Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. , 2006, Blood.

[36]  M. Caligiuri,et al.  Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. , 2006, The Journal of clinical investigation.

[37]  D. Reinhardt,et al.  Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Bloomfield,et al.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  R. Pieters,et al.  High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9 , 2006, Genes, chromosomes & cancer.

[40]  R. Hills,et al.  Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials , 2005, Leukemia.

[41]  C. Zwaan,et al.  Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials , 2005, Leukemia.

[42]  U. Creutzig,et al.  Pediatric acute myeloid leukemia: international progress and future directions , 2005, Leukemia.

[43]  G. Henze,et al.  Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials , 2005, Leukemia.

[44]  S. Armstrong,et al.  Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. , 2005, Blood.

[45]  S. Meshinchi,et al.  Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia , 2005, Leukemia.

[46]  J. Radich,et al.  FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. , 2003, Blood.

[47]  M. D. Boer,et al.  Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[49]  J. Reilly,et al.  Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias , 2003, British journal of haematology.

[50]  J. Downing,et al.  Acute leukemia: a pediatric perspective. , 2002, Cancer cell.

[51]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[52]  T. Ley,et al.  PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  B. Smith,et al.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.

[54]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[55]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[56]  T. Naoe,et al.  Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia , 1997, Leukemia.

[57]  D. Tenen,et al.  Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[58]  M. Caligiuri,et al.  Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. , 1996, Cancer research.

[59]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[60]  C. Bloomfield,et al.  Cytogenetics of Acute Leukemia , 2013 .

[61]  C. Zwaan,et al.  TET2 mutations in childhood leukemia , 2011, Leukemia.

[62]  R. Pieters,et al.  University of Groningen Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia Hollink, , 2011 .

[63]  R. Arceci.  Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial , 2011 .

[64]  R. Arceci.  Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study , 2010 .

[65]  R. Pieters,et al.  Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML , 2009, Leukemia.

[66]  C. S. Swindle,et al.  FLT 3-ITD cooperates with inv ( 16 ) to promote progression to acute myeloid leukemia , 2008 .

[67]  R. Arceci.  Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98 , 2008 .

[68]  Bob Löwenberg,et al.  Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. , 2003, The hematology journal : the official journal of the European Haematology Association.

[69]  T. Ley,et al.  PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[70]  山本 幸也,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies , 2002 .

[71]  D. Fabbro,et al.  Inhibition of mutant FLT 3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC 412 , 2002 .

[72]  I. Bernstein,et al.  Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. , 2001, Blood.

[73]  I. Bernstein,et al.  Prevalence and prognostic significance of Flt 3 internal tandem duplication in pediatric acute myeloid leukemia , 2000 .

[74]  F. Behm,et al.  Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. , 1999, Blood.

[75]  G. Ehninger,et al.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. , 2002, Blood.